|
|
||||||||

*
Institut National de la Santé et de la Recherche Médicale Unité 345, Institut Necker, and
Centre National de la Recherche Scientifique, Unité de Recherche Associée 583, Hôpital Necker, Paris, France
| Abstract |
|---|
|
|
|---|
inducer polyinosinic:polycytidylic acid,
infection by the BM5 variants of murine leukemia virus (the causative
agent of murine AIDS), and T cell expansion after transfer of normal
bone marrow and lymph node cells into recombinase-activating
gene-2-deficient mice. In each case, a peak of T cell proliferation was
observed in blood. These data demonstrate the extensive redistribution
of cycling T cells in the first few hours after activation. Kinetic
studies of blood lymphocyte status appear crucial for understanding
primary immune responses because cycling and redistributing T
lymphocytes are enriched in the circulating
compartment. | Introduction |
|---|
|
|
|---|
In normal animals, very small numbers of cycling mature lymphocytes are detected in peripheral lymphoid organs (9, 10). We used a BrdU pulse-labeling protocol, with one or two injections separated by a period shorter than the S phase duration. This technique can locate cycling cells and was preferred to continuous BrdU administration which cumulatively labels the progeny of cycling precursors (11, 12), T cells labeled at the ultimate step of intrathymic cell maturation (13), and cycling peripheral cells.
To define the kinetics of cell activation and to delineate specific and bystander responses, we focused on cell proliferation after injection of the bacterial superantigen Staphylococcus enterotoxin B (SEB)3 (14), which induces specific activation and deletion of T cells expressing the Vß8 families of the TCR (15, 16). Polyinosinic:polycytidylic acid (poly(I:C)) injection mimics viral infection by inducing the production of lymphokines (particularly type I IFN) (17). Infection by the LP-BM5 virus combination, a mixture of deficient Moloney murine leukemia virus (MuLV) viruses, induces murine acquired immunodeficiency syndrome (MAIDS) (18). In all these systems we found that cell proliferation was higher in blood than in lymph nodes (LN) and spleen. We also tested T cell proliferation during lymphocyte expansion after transfer of exogenous T cells and precursors into an immunodeficient host and found a high level of DNA synthesis in blood.
| Materials and Methods |
|---|
|
|
|---|
All experiments were done with 6- to 8-wk-old C57BL/6 (B6) mice bred in our own facilities or purchased from Charles River (Cléon, France). B6 recombinase-activating gene-2-deficient (RAG-2-/-) mice were obtained from (Centre de Developpement des Techniques Avaucets, Orléans, France).
In vivo T cell stimulation systems
On day 0 of the experiments, mice received an i.p. injection of 10 µg of SEB (Sigma, St. Louis, MO), poly(I:C) (Sigma, 150 µg in 100 µl of PBS), or 0.3 ml of supernatant from the SC-1 cell clone infected by LP-BM5 MuLV and kindly supplied by H. C. Morse III (National Institutes of Health, Bethesda, MD). Control mice were injected with the same volume of PBS or uninfected SC-1 cell supernatant.
Lymphocyte reconstitution
Irradiated (3 Gy) RAG-2-deficient mice were injected i.v. with a mixture of mouse T cell-depleted bone marrow (BM) and total LN cells (3 x 106 each) from C57BL/6 mice.
BrdU labeling
At various times (2 h to several weeks) after injection of the activating agent or cell transfer, 1 mg of BrdU (Sigma) in 100 µl of PBS was injected i.p., twice at a 1-h interval.
Thirty minutes after the second BrdU injection (90 min after the first), lymphoid organs (thymus, mesenteric lymph nodes (MLN), and spleen) and blood samples were harvested for BrdU detection. With this injection protocol, we labeled DNA-synthesizing cells only, and not their postmitotic progeny. As indicated in Results, in some experiments this standard protocol was slightly modified by using only one BrdU injection or by extending the delay between BrdU injection and detection.
Cell staining and immunofluorescence
Cell suspensions were prepared and counted, and blood samples were then centrifuged on Ficoll gradients. All suspensions were prepared in ice-cold PBS containing 4% FCS and 0.2% sodium azide (Sigma). Surface molecules were stained with the following sets of three fluorochrome-conjugated mAbs: tricolor-conjugated anti-CD4 (Caltag, San Francisco, CA), PE-conjugated anti-CD8, and biotinylated anti-TCR ß-chain (clone H57/97); anti-Vß8.2 (clone F23.2) or Vß6 (clone 44.22.1) TCR chain, anti-CD69 (clone H1.2F3), anti-CD44 (clone 1 M681), anti-CD62L (MEL-14), or anti-ICAM-1 (PharMingen, San Diego, CA). Most of the biotinylated Abs were prepared in our laboratory, and binding was revealed with allophycocyanin-conjugated streptavidin (Molecular Probes, Eugene, OR).
After surface staining, cells were fixed and permeabilized in PBS containing 1% paraformaldehyde and 0.01% Tween 20 for 48 h at 4°C. BrdU was then detected by using a published method (19) including DNase I cell treatment, with a FITC-conjugated anti-BrdU Ab (Becton Dickinson, San Jose, CA) or with the anti-BrdU Ab 76/7 (a gift from T. Ternynck, Institut Pasteur, Paris, France); revelation was done with FITC-conjugated goat anti-mouse IgG1 (Southern Biotechnology, Birmingham, AL).
Four-color immunofluorescence was analyzed in a FACScalibur cytometer (Becton Dickinson), using the Cell Quest program. Nonlymphoid cells, dead cells, and aggregates were eliminated by using an electronic gate set on forward and side light scatter.
| Results |
|---|
|
|
|---|
Thirty minutes after the second BrdU injection, the percentage of labeled cells was higher in blood (0.8 ± 0.2% in CD4 T cells and 1.7 ± 0.3% in CD8 T cells) than in LN and spleen (<0.5% in all subsets). These relative frequencies do not directly reflect the absolute numbers of cycling T cells present in the different compartments, because blood contains only 2% of the total T lymphocyte pool (20). Normal peripheral cycling T cells are all CD44+, and have a conventional activation phenotype (A. Le Campion et al., unpublished results); they are likely to result from a recent TCR/Ag reaction that requires contact between T cells and APCs and is more likely to occur in organs than in the circulating compartment (21). We thus postulated that cycling cells found in blood might be activated cells having recently migrated from organs, and we explored the distribution of cycling T cells during experimental immune responses.
T cell response to the bacterial superantigen SEB
To study the kinetics and specificity of the proliferative T cell response, we used SEB as an in vivo stimulator. The superantigen was injected i.p. to elicit a systemic response. This system has several advantages: the response to SEB is very rapid and involves a large number of Ag-specific T lymphocytes (all those expressing the Vß8 TCR families); the bystander response can be evaluated by measuring the proliferative response of nonspecific cells (Vß6+ cells in our experiments).
Kinetics and specificity of SEB-induced T cell proliferation
The percentages of BrdU+ cells among mature
SEB-specific and nonspecific CD4SP and CD8SP cells were determined in
blood, thymus, MLN, and spleen after a 1-h double pulse with the
nucleoside (Fig. 1
). Peaks of DNA
synthesis by Vß8+ cells were found in all organs tested.
CD4 SP cell proliferation was maximal 1624 h after SEB injection and
was higher in blood than in LN, spleen, and thymus: 24 h after SEB
injection the mean percentages of
BrdU+CD4+Vb8+ cells were 27% in
blood, 14.5% in LN, 13.5% in spleen, and 3.4% in thymus. This
proliferative activity was much stronger in Vß8+
SEB-specific cells: BrdU incorporation by
CD4+Vß6+ cells was augmented in blood only
relative to the control (4.6% at 24 h post-SEB).
CD8+Vß8+ cell proliferation also started at
16 h and lasted longer in blood (still at the plateau on day 2).
Vß8highCD8 SP thymocytes showed a transient and intense
wave of DNA synthesis (
20% BrdU+ cells at 1624 h). In
blood, Vß6+ cell stimulation was stronger in the CD8
subset (8% at 24 h) than in the CD4 subset. In all four
compartments tested, BrdU incorporation was thus much higher in
Vß8+ cells than in Vß6+ cells. However, as
shown in Fig. 2
A, the
proportion of Vß8+ cells among DNA-synthesizing T cells
was only 3050%. The question arises as to whether
Vß8- cell proliferation is a bystander response. Tough
et al. (17) reported that injection of type I IFN induced CD8 cell
proliferation and defined this as bystander response because it was not
accompanied by CD69 expression. We compared CD69 expression by
BrdU+ cells detected 16 h after SEB injection by
labeling blood, LN, and spleen cells with anti-CD4 (or
anti-CD8) plus anti-Vß8, anti-CD69, and anti-BrdU.
The 16-h time point was preferred to 24 h because, as shown in
Fig. 5
, the early activation marker CD69 starts to be down-regulated by
24 h. The BrdU/CD69 dot plots of gated CD4+ or
CD8+ cells positive or negative for Vß8 expression are
represented in Fig. 2
B. More than 90% of cycling
Vß8+ cells were CD69high in all compartments,
and the proportion was only slightly lower in
BrdU+Vß8- T cells (7895%, depending on
the subset and compartment). SEB-induced BrdU+ cells all
expressed a CD44high, CD62Llow, and
ICAM-1high phenotype (data not shown). These data suggest
that most Vß8- cycling cells might result from a
TCR-mediated cross-reaction to SEB and that bystander proliferation is
minimal in this system. Similar results were obtained when we examined
CD69 expression by cycling Vß6+ cells, but the small
number of cells obtained, particularly in blood, prevented us from
obtaining quantitatively significant data. Incidentally, we observed
that the percentages of BrdU+ cells were higher among total
Vß8- cells than among Vß6+ cells (Fig. 2
A). SEB induces Vß3+ cell proliferation (data
not shown), and it is also possible that a significant proportion of
Vß8+ responding cells down-regulated TCR expression, at
least during DNA synthesis.
|
|
|
We then determined the origin of cycling T cells present in blood.
The period between the first BrdU injection and detection of labeled
cells (90 min in our standard protocol) may be sufficient for resident
cells labeled during late S phase to complete DNA synthesis, divide,
and migrate from organs to blood. We therefore examined BrdU
incorporation 30 min after a single BrdU injection given 24 h
after SEB. The percentages of BrdU-labeled Vß8+ cells
found in all the compartments were not significantly different from
values obtained with the standard two-injection protocol, and the
relative distribution of cycling cells in blood and lymph nodes was the
same (Fig. 3
). This shows that
SEB-reactive T lymphocytes synthesize DNA, and then divide, in the
blood compartment. It does not mean, however, that circulating cycling
cells were initially activated in blood.
|
To evaluate cell migration and initial activation events, we
investigated changes in the absolute numbers of T cells after SEB
injection and studied the expression kinetics of the activation markers
CD69 and CD44. Changes in the absolute numbers of CD4+ and
CD8+Vß8+ cells in blood, MLN, and spleen
during the first 72 h after SEB injection are shown in Fig. 4
. In blood, we observed an immediate,
sharp fall in the number of SEB-specific cells: 90% of blood
Vß8+ cells disappeared within 2 h. Their numbers
showed a further increase at 24 h and then plateaued at numbers
slightly higher than in controls. Similar but slower changes in
SEB-specific cell numbers were observed in the spleen, in which the
numbers of CD4+ and CD8+Vß8+
cells were reduced by 50% after 16 h. During the same period,
Vß8+ CD4+ cell numbers transiently increased
in MLN. SEB-nonspecific cells expressing Vß6 were also depleted from
blood, but much less markedly than Vß8+ T cells; in
contrast, their numbers did not change significantly in LN and spleen.
The most likely interpretation for these data is that SEB-responsive
cells are transiently trapped in specialized lymphoid organs
(particularly LN) where the Ag is presented and then return to the
circulation after activation. If this is so, activation markers might
be detectable earlier in LN than in blood. We therefore compared the
kinetics of DNA synthesis and CD69 and CD44 expression in the different
compartments. The data obtained during the first 48 h after SEB
injection are presented in Fig. 5
. CD69
induction always preceded DNA synthesis, but CD69 induction was clearly
more rapid in LN and spleen than in blood; 4 h after SEB injection
the proportions of CD69+ cells among
Vß8+CD4+ cells were 94% in LN and 86% in
spleen but only 48% in blood. Similar differences were observed with
CD8+ cells. These data confirm that SEB-specific cells are
first activated in LN and spleen and then circulate in the blood. The
changes in CD44 expression by LN and spleen Vß8+ cells
were much slower than the changes in CD69 expression. CD44 expression
increased significantly during the second day only, after the peak of
DNA synthesis. By contrast, the proportion of
CD44high cells among blood Vß8+ cells
increased early and sharply. This enrichment in CD44high
cells coincided with the drop in total Vß8+ blood cell
numbers; it was probably due more to preferential trapping of blood
CD44- cells in LN than to activation-linked CD44
up-regulation.
|
|
1.5-fold during the 24
h following BrdU injection, and most BrdU+ cells found on
day 2 in these conditions were no longer cycling (Fig. 6Globally, the results obtained with the SEB system suggest that Ag-specific T cells first encounter the Ag in organs, in which APCs are located, and then recirculate after entering the activation cascade (this includes DNA synthesis, which is readily detectable in blood).
The redistribution process described above could be SEB specific; alternatively, it could be a general rule governing immune responses. To test these possibilities, we assayed T cell proliferation in two stimulation systems excluding bacterial superantigens and during lymphoid development in mouse chimeras.
Poly(I:C) stimulation
Tough et al. (17) have shown that activation of lymphoid cells by
virus in vivo can be mimicked by injecting the IFN-I inducer poly(I:C).
We repeated this experiment and measured the labeling index in
CD44high lymphocytes in blood and MLN. As shown in Table I
, BrdU incorporation was maximum on day
2 after poly(I:C) injection in both lymphocyte subsets and 2.5- to
5-fold higher in blood than in LN.
|
The MuLV-derived LP-BM5 virus preparation used here induces a
MAIDS, sharing certain aspects with human AIDS (18). We studied the
kinetics of BrdU incorporation in blood, MLN, and spleen
CD44high lymphocytes during the first 2 wk after virus
infection. The results are presented in Fig. 7
. In blood, T cell proliferation began
to increase on day 6, peaked on day 8, and returned to normal values on
day 10. It was much higher in CD4-CD8+ cells
(16.5 ± 3.9% on day 8) than in CD4+CD8-
cells (5.7 ± 0.7%). In LN and spleen, a very small increase in
BrdU incorporation was observed on day 6 and was similar in
CD4+ and CD8+ cells.
|
Peripheral T cell proliferation during lymphoid reconstitution
To determine whether the distribution of cycling peripheral T
cells described above is specific to responses to exogenous
stimulators, we studied BrdU incorporation by LN and blood CD4 and CD8
T cells from chimeric mice prepared by transfer of normal BM cells
alone or combined with syngeneic LN T cells into
B6/RAG-2-/- recipients. The results, presented in Fig. 8
, show that BrdU incorporation by blood
and LN T cells increased strongly during the third week after transfer,
decreased at week 4, and returned to values similar to those in normal
adult B6 mice by 6 wk. LN cellularity was 30% of normal at 4 wk, and
normal at 6 wk. In RAG-2-/- mice transferred with BM
cells only, the first CD4+ and CD8+ cells
appeared in the periphery on days 18 and 21, respectively, and also
proliferated strongly (A. Le Campion et al., unpublished results). In
this system, T cell proliferation was not higher in blood than in
organs, but these data confirm that newly produced or transferred
mature T cells are able to expand in the deprived periphery and that
this proliferation is readily detectable in blood, as during immune
responses.
|
| Discussion |
|---|
|
|
|---|
T cell proliferation in blood was not a bystander, lymphokine-induced process. Even in the CD8 blood subset, the proliferative response of Vß8+ cells was much stronger than the response of Vß6+ cells. Tough et al. (17) have suggested that during antiviral responses, most proliferating cells are not Ag specific and are stimulated by lymphokines (a bystander response). Limit dilution analysis-based calculations of the frequencies of Ag-specific responder cells have given very low values in several different systems (24, 25, 26). The notion of a prominent bystander response has recently been challenged by a series of reports in which the specificity of the response in vivo was examined directly (27, 28, 29, 30, 31). In these studies, the calculated frequency of Ag-specific cells was at least 5070% of all responding cells, a result coherent with our present data. Even the Vß8- cell response to SEB did not appear to be a pure lymphokine-induced bystander process, because most cycling Vß8-, and particularly Vß6+ cells, were CD69high. However, more cells incorporated BrdU in the total Vß8- population than in the Vß6+ population. Two possible explanations for this difference can be forwarded: SEB also stimulates Vß3+ cells; and a large proportion of SEB-responding cells might down-regulate TCR surface expression.
The kinetics of T cell proliferation varied in the different stimulation systems, peak DNA synthesis occurring on day 1 with SEB, on day 2 with poly(I:C), and on day 8 with LP-BM5 MuLV. These differences are probably related to different modes of Ag presentation: poly(I:C) directly induces IFN production; and SEB presentation is direct and occurs with minimal Ag processing compared with LP-BM5 viral peptides. Hayden et al. (32) have shown that injection of Mtv-7-positive (Mls-1a) cells also induces a proliferative response by specific (Vß6+) cells; in this system, BrdU was continuously infused, and only 2% of CD4+Vß6+ LN cells were labeled on day 1; this percentage increased to 40% on day 3 and to 70% on day 4 (cumulative labeling). The 1-day delay observed relative to the SEB system probably corresponds to Ag processing and presentation.
Superantigen-induced apoptosis was not measured in our study. Working with C3H (I-E+) mice, dAdamio et al. (33) suggested that SEB-induced expansion of LN Vß8+ cells is preceded by significant depletion. However, Renno et al. (34), combining cumulative BrdU labeling and apoptotic cell detection, observed that only postmitotic cells underwent apoptosis. It has recently been reported (35) that although Fas and apoptosis-inducing genes were rapidly induced after SEB injection, apoptosis-preventing gene products (particularly bag-1) were transiently up-regulated on the first day, simultaneously with LN and spleen Vß8+ cell blastogenesis and before the appearance of apoptotic cells. These recent data strongly suggest that SEB-specific cell proliferation precedes apoptosis.
We found that the highest percentage of cycling cells was in blood, at a time when the global number of specific cells was strongly reduced in this compartment. The initial depletion in blood probably reflects specific cell trapping in peripheral lymphoid organs, as observed for Vß6+ cells accumulating in the draining LN after local injection of mammary tumor virus (36). With the soluble superantigen SEB, T cell accumulation in LN is very transient, and proliferating cells recirculate in the blood rapidly after superantigen presentation and activation. Thymic SEB-reactive cells (mainly Vß8+CD8SP cells), which are also stimulated, could also emigrate to blood after starting DNA synthesis, as we have recently demonstrated in normal, noninfected mice (13), but their participation appears quantitatively marginal, given that the global process described here was not modified by adult thymectomy.
The total number of peripheral blood T lymphocytes represents a low
proportion (
2%) of the total T cell pool (20), and preferential
recirculation of Ag-specific cycling cells will result in a strong
increase in their frequency in the blood. In this respect, blood
appears to be a sort of "magnifying glass" for following the immune
response. Recently, Pantaleo et al. (37) showed that during primary HIV
infection, HIV-specific clones accumulated preferentially in blood
rather than in LN and that this accumulation preceded virus clearance
from both compartments. Such data are lacking in mouse systems, in
which the blood compartment has often been neglected. Our results
validate human PBL-based investigations, at least for the follow-up of
acute infections. In addition, we demonstrate that cycling T cells also
circulate in the blood during peripheral expansion accompanying
lymphoid generation, in the absence of experimental infection. This
finding suggests that the fate of cycling T cells may be similar in the
two systems (homeostatic expansion and Ag-induced proliferation).
The role of "pure" homeostatic expansion in CD4+ T cell regeneration during efficient treatment of HIV infection, which was initially thought to be virtually exclusive (5, 6, 7), has been questioned following the observation of the physiology and kinetics of memory and naive cell increase (38, 39, 40, 41). We detected no increase in PBL proliferation during the chronic phase of HIV infection in patients on triple-drug antiretroviral therapy, with the exception of patients who had acute opportunistic infections (4). These data and our present results suggest that in vivo proliferation of mature T cells is mainly Ag driven.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Claude Pénit, INSERM U.345, Institut Necker, 156 Rue de Vaugirard, 75730 Paris Cedex 15, France. E-mail address: ![]()
3 Abbreviations used in this paper: SEB, Staphylococcus enterotoxin B; MAIDS, murine AIDS; LN, lymph nodes; MLN, mesenteric LNs; RAG, recombinase-activating gene; SP, single-positive; poly(I:C), polyinosinic:polycytidylic acid; MuLV, Moloney murine leukemia virus; BM, bone marrow. ![]()
Received for publication August 31, 1998. Accepted for publication February 9, 1999.
| References |
|---|
|
|
|---|
ß and 
T cell subsets in viral immunity. Annu. Rev. Immunol. 10:123.[Medline]
This article has been cited by other articles:
![]() |
A. Jabbari, K. L. Legge, and J. T. Harty T cell conditioning explains early disappearance of the memory CD8 T cell response to infection. J. Immunol., September 1, 2006; 177(5): 3012 - 3018. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. N. Hwang, Z. Yu, D. C. Palmer, and N. P. Restifo The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor Cancer Res., January 15, 2006; 66(2): 1132 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Maxwell, R. J. Rossi, S. J. McSorley, and A. T. Vella T Cell Clonal Conditioning: A Phase Occurring Early after Antigen Presentation but before Clonal Expansion Is Impacted by Toll-Like Receptor Stimulation J. Immunol., January 1, 2004; 172(1): 248 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Benlhassan-Chahour, C. Penit, V. Dioszeghy, F. Vasseur, G. Janvier, Y. Riviere, N. Dereuddre-Bosquet, D. Dormont, R. Le Grand, and B. Vaslin Kinetics of Lymphocyte Proliferation during Primary Immune Response in Macaques Infected with Pathogenic Simian Immunodeficiency Virus SIVmac251: Preliminary Report of the Effect of Early Antiviral Therapy J. Virol., December 1, 2003; 77(23): 12479 - 12493. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lippert, D. L. Yowe, J.-A. Gonzalo, J. P. Justice, J. M. Webster, E. R. Fedyk, M. Hodge, C. Miller, J.-C. Gutierrez-Ramos, F. Borrego, et al. Role of Regulator of G Protein Signaling 16 in Inflammation- Induced T Lymphocyte Migration and Activation J. Immunol., August 1, 2003; 171(3): 1542 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mohrs, D. A. Lacy, and R. M. Locksley Stat Signals Release Activated Naive Th Cells from an Anergic Checkpoint J. Immunol., February 15, 2003; 170(4): 1870 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Le Campion, C. Bourgeois, F. Lambolez, B. Martin, S. Leaument, N. Dautigny, C. Tanchot, C. Penit, and B. Lucas Naive T cells proliferate strongly in neonatal mice in response to self-peptide/self-MHC complexes PNAS, April 2, 2002; 99(7): 4538 - 4543. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Y. Choi, Y. Yoshimura, G. J. Christianson, T. J. Sproule, S. Malarkannan, N. Shastri, S. Joyce, and D. C. Roopenian Quantitative Analysis of the Immune Response to Mouse Non-MHC Transplantation Antigens In Vivo: The H60 Histocompatibility Antigen Dominates Over All Others J. Immunol., April 1, 2001; 166(7): 4370 - 4379. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Jelley-Gibbs, N. M. Lepak, M. Yen, and S. L. Swain Two Distinct Stages in the Transition from Naive CD4 T Cells to Effectors, Early Antigen-Dependent and Late Cytokine-Driven Expansion and Differentiation J. Immunol., November 1, 2000; 165(9): 5017 - 5026. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Le Campion, C. Bourgeois, F. Lambolez, B. Martin, S. Leaument, N. Dautigny, C. Tanchot, C. Penit, and B. Lucas Naive T cells proliferate strongly in neonatal mice in response to self-peptide/self-MHC complexes PNAS, April 2, 2002; 99(7): 4538 - 4543. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |